Cancer Family
Giant Cell Neoplasm
CI-CAN-00000020Explore in graph →
Non-malignant22 active trials3 evidence items
- NCIt
- C7069
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000020Explore in graph →
Clinical trials
158 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03866382 | Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors | recruiting | Phase 2 | 314 | National Cancer Institute (NCI)NIH | 2 | Sep 29, 2026 | clinicaltrials |
| NCT07832747 | A Study of DCC-3014 to Evaluate the Efficacy, Safety, and Pharmacokinetics in Subjects With TGCT | not yet recruiting | Phase 2 | 18 | Ono Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 22, 2026 |
| clinicaltrials |
| NCT07667335 | Enfortumab Vedotin, Pembrolizumab and Quemliclustat for the Treatment of Unresectable Locally Advanced and Metastatic Urothelial Cancer | recruiting | Phase 1 / Phase 2 | 27 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT07499362 | Study of Pimicotinib in Japanese Participants With Tenosynovial Giant Cell Tumor (TGCT) (J-MANEUVER) | recruiting | Phase 2 | 20 | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, GermanyINDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06239272 | NRSTS2021, A Risk Adapted Study Evaluating Maintenance Pazopanib, Limited Margin, Dose-Escalated Radiation Therapy and Selinexor in Non-Rhabdomyosarcoma Soft Tissue Sarcoma (NRSTS) | recruiting | Phase 1 / Phase 2 | 139 | St. Jude Children's Research HospitalOTHER | 1 | Aug 3, 2026 | clinicaltrials |
| NCT07707882 | Neoadjuvant Pimicotinib Combined With Surgery Versus Upfront Surgery for Diffuse Tenosynovial Giant Cell Tumor(NEXPERT) | not yet recruiting | Phase 2 | 84 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT03069469 | Study of Vimseltinib (DCC-3014) in Patients With Advanced Tumors and Tenosynovial Giant Cell Tumor | active not recruiting | Phase 1 / Phase 2 | 120 | Deciphera Pharmaceuticals, LLCINDUSTRY | 9 | Jun 25, 2026 | clinicaltrials |
| NCT04703322 | A Study of Pexidartinib in Tenosynovial Giant Cell Tumor in Japan | completed | Phase 2 | 9 | Daiichi Sankyo Co., Ltd.INDUSTRY | 1 | Jun 24, 2026 | clinicaltrials |
| NCT02834013 | Nivolumab and Ipilimumab in Treating Patients With Rare Tumors | active not recruiting | Phase 2 | 798 | National Cancer Institute (NCI)NIH | 2 | Jun 17, 2026 | clinicaltrials |
| NCT05218408 | CYNK-001 IV and IC in Combination With IL2 in Surgical Eligible Recurrent GBM With IDH-1 Wild Type(CYNK001GBM02) | withdrawn | Phase 1 / Phase 2 | 0 | Celularity IncorporatedINDUSTRY | 0 | Jun 8, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT01207492 | Nilotinib in Patients With Relapsed or Metastatic Pigmented Villonodular Synovitis/Tenosynovial Giant Cell Tumor/Diffuse-Type Giant Cell Tumor | completed | Phase 2 | 17 | Andrew J. Wagner, MD, PhDOTHER | 1 | Feb 20, 2026 | clinicaltrials |
| NCT04482933 | HSV G207 With a Single Radiation Dose in Children With Recurrent High-Grade Glioma | withdrawn | Phase 2 | 0 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Feb 10, 2026 | clinicaltrials |
| NCT01894061 | NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma | completed | Phase 2 | 25 | Case Comprehensive Cancer CenterOTHER | 1 | Feb 17, 2025 | clinicaltrials |
| NCT06647901 | Efficacy of ICG-based NIR Imaging in Intralesional Curettage of Giant Cell Tumors of Bone in Limbs: a Prospective, Single-center, Single-arm, Open Study | recruiting | Phase 1 / Phase 2 | 45 | Tang XiaodongOTHER | 1 | Oct 18, 2024 | clinicaltrials |
| NCT01149850 | Bevacizumab and Temozolomide in Treating Older Patients With Newly-Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05349643 | A Study to Evaluate Safety and Efficacy of AMB-05X Injections in Subjects With TGCT | completed | Phase 2 | 20 | AmMax Bio, Inc.INDUSTRY | 3 | Jul 5, 2024 | clinicaltrials |
| NCT04731675 | An Open-Label Study of Intra-articular AMB-05X Injections in Subjects With Tenosynovial Giant Cell Tumor of the Knee | completed | Phase 2 | 11 | AmMax Bio, Inc.INDUSTRY | 4 | Jun 27, 2024 | clinicaltrials |
| NCT04938180 | A Phase 2 Study of Intravenous AMB-05X in Tenosynovial Giant Cell Tumor Patients | terminated | Phase 2 | 4 | AmMax Bio, Inc.INDUSTRY | 3 | May 24, 2024 | clinicaltrials |
| NCT03027388 | Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma | completed | Phase 2 | 7 | National Cancer Institute (NCI)NIH | 1 | Nov 22, 2023 | clinicaltrials |
| NCT03912818 | Durvalumab and Standard Chemotherapy Before Surgery in Treating Patients With Variant Histology Bladder Cancer | terminated | Phase 2 | 7 | Stanford UniversityOTHER | 1 | Sep 11, 2023 | clinicaltrials |
| NCT02366728 | DC Migration Study for Newly-Diagnosed GBM(ELEVATE) | completed | Phase 2 | 64 | Mustafa Khasraw, MBChB, MD, FRCP, FRACPOTHER | 1 | Jun 8, 2023 | clinicaltrials |
| NCT00662506 | Cediranib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma | completed | Phase 1 / Phase 2 | 46 | National Cancer Institute (NCI)NIH | 1 | Jun 6, 2023 | clinicaltrials |
| NCT05595603 | Zoledronic Acid-loaded Bone Cement as a Local Adjuvant Therapy for Giant Cell Bone Tumor After Intralesional Curettage | recruiting | Phase 2 | 153 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Mar 15, 2023 | clinicaltrials |
| NCT01730950 | Bevacizumab With or Without Radiation Therapy in Treating Patients With Recurrent Glioblastoma | completed | Phase 2 | 182 | Radiation Therapy Oncology GroupNETWORK | 1 | Dec 29, 2022 | clinicaltrials |
| NCT00396279 | Safety and Efficacy Study of Denosumab in Patients With Recurrent or Unresectable Giant Cell Tumor of Bone | completed | Phase 2 | 37 | AmgenINDUSTRY | 0 | Nov 8, 2022 | clinicaltrials |
| NCT04255576 | Efficacy and Safety of JMT103 in Patients With Giant Cell Tumor of Bone | unknown | Phase 1 / Phase 2 | 139 | Shanghai JMT-Bio Inc.INDUSTRY | 1 | Oct 14, 2022 | clinicaltrials |
| NCT00680992 | Study of Denosumab in Subjects With Giant Cell Tumor of Bone | completed | Phase 2 | 535 | AmgenINDUSTRY | 12 | Sep 22, 2022 | clinicaltrials |
| NCT00731731 | Vorinostat, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 125 | National Cancer Institute (NCI)NIH | 1 | Aug 4, 2022 | clinicaltrials |
| NCT01609790 | Bevacizumab With or Without Trebananib in Treating Patients With Recurrent Brain Tumors | completed | Phase 2 | 137 | National Cancer Institute (NCI)NIH | 2 | Jul 21, 2022 | clinicaltrials |
| NCT02471716 | Study of Cabiralizumab in Patients With Pigmented Villonodular Synovitis / Diffuse Type Tenosynovial Giant Cell Tumor(FPA008-002) | completed | Phase 1 / Phase 2 | 66 | Five Prime Therapeutics, Inc.INDUSTRY | 6 | Aug 31, 2021 | clinicaltrials |
| NCT01051557 | Temsirolimus and Perifosine in Treating Patients With Recurrent or Progressive Malignant Glioma | completed | Phase 1 / Phase 2 | 36 | National Cancer Institute (NCI)NIH | 1 | Jul 19, 2021 | clinicaltrials |
| NCT03620149 | Reduced Dose-density of Denosumab for Unresectable GCTB(REDUCE) | terminated | Phase 2 | 2 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Jan 6, 2021 | clinicaltrials |
| NCT01643850 | MCS110 in Patients With Pigmented Villonodular Synovitis (PVNS) | completed | Phase 2 | 36 | Novartis PharmaceuticalsINDUSTRY | 2 | Jan 5, 2021 | clinicaltrials |
| NCT00052208 | Gefitinib and Radiation Therapy in Treating Patients With Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 158 | National Cancer Institute (NCI)NIH | 1 | Oct 30, 2020 | clinicaltrials |
| NCT03014804 | Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma | withdrawn | Phase 2 | 0 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Jul 24, 2020 | clinicaltrials |
| NCT01478321 | Efficacy of Hypofractionated XRT w/Bev. + Temozolomide for Recurrent Gliomas | terminated | Phase 2 | 54 | Northwestern UniversityOTHER | 1 | Mar 12, 2020 | clinicaltrials |
| NCT01498328 | A Study of Rindopepimut/GM-CSF in Patients With Relapsed EGFRvIII-Positive Glioblastoma(ReACT) | completed | Phase 2 | 127 | Celldex TherapeuticsINDUSTRY | 1 | Feb 17, 2020 | clinicaltrials |
| NCT01806675 | 18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy | completed | Phase 1 / Phase 2 | 25 | Sanjiv Sam GambhirOTHER | 1 | Oct 3, 2019 | clinicaltrials |
| NCT01514201 | Veliparib, Radiation Therapy, and Temozolomide in Treating Younger Patients With Newly Diagnosed Diffuse Pontine Gliomas | completed | Phase 1 / Phase 2 | 66 | National Cancer Institute (NCI)NIH | 1 | Aug 13, 2019 | clinicaltrials |
| NCT00423735 | Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 2 | 64 | National Cancer Institute (NCI)NIH | 3 | Jul 24, 2019 | clinicaltrials |
| NCT00902577 | MRI and PET/FMISO In Assessing Tumor Hypoxia in Patients With Newly Diagnosed Glioblastoma Multiforme | completed | Phase 2 | 50 | National Cancer Institute (NCI)NIH | 1 | Apr 8, 2019 | clinicaltrials |
| NCT00464620 | Trial of Dasatinib in Advanced Sarcomas | completed | Phase 2 | 366 | Sarcoma Alliance for Research through CollaborationOTHER | 1 | Nov 23, 2018 | clinicaltrials |
| NCT01977677 | Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma | completed | Phase 1 / Phase 2 | 30 | Lawrence RechtOTHER | 1 | Oct 23, 2018 | clinicaltrials |
| NCT01575275 | Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme | terminated | Phase 2 | 8 | Michael Vogelbaum, MD, PhDOTHER | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01836549 | Imetelstat Sodium in Treating Younger Patients With Recurrent or Refractory Brain Tumors | terminated | Phase 2 | 43 | Pediatric Brain Tumor ConsortiumNETWORK | 1 | Jul 20, 2018 | clinicaltrials |
| NCT00335764 | Sorafenib Combined With Erlotinib, Tipifarnib, or Temsirolimus in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 92 | National Cancer Institute (NCI)NIH | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01648348 | Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme | completed | Phase 1 / Phase 2 | 116 | National Cancer Institute (NCI)NIH | 1 | May 23, 2018 | clinicaltrials |
| NCT00305864 | Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma | completed | Phase 1 / Phase 2 | 118 | National Cancer Institute (NCI)NIH | 1 | Mar 5, 2018 | clinicaltrials |
| NCT01753713 | Dovitinib in Treating Patients With Recurrent or Progressive Glioblastoma | completed | Phase 2 | 33 | Manmeet Ahluwalia, MDOTHER | 1 | Dec 12, 2017 | clinicaltrials |
Data updated 11 hours agoSource updated Sep 29, 2026source: clinicaltrials